Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...

The human immune system is a complex network of cells and signals that guards against disease, yet in the case of cancer, it ...

胶质母细胞瘤 ...

Instead, we're recruiting healthy soldiers from disease-free, well donors and equipping them with special targeting systems ...

The discovery could help explain why some cancer patients respond well to certain treatments, while others are not so lucky.

BGB-10188 is under clinical development by BeiGene and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Renal Cell Carcinoma have a 29% phase transition ...

Telisotuzumab adizutecan is under clinical development by AbbVie and currently in Phase I for Renal Cell Carcinoma.

A new study uncovers how a novel immunotherapy prevents squamous cell carcinoma, with benefits lasting five years after treatment. This therapy is the first to activate specific components of the ...

GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, Bristol Myers Squibb's anti-PD-1 therapy, as ...

This manuscript offers valuable insights by identifying two distinct liver cancer subtypes through multi-omics integration and developing a robust prognostic model, validated across various datasets, ...

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...